Rocket Pharmaceuticals, Inc. Common Stock (RCKT) is a publicly traded Healthcare sector company. As of May 21, 2026, RCKT trades at $3.03 with a market cap of $335.22M and a P/E ratio of -1.47. RCKT moved +1.37% today. Year to date, RCKT is -16.34%; over the trailing twelve months it is -56.64%. Its 52-week range spans $2.19 to $18.89. Analyst consensus is buy with an average price target of $9.67. Rallies surfaces RCKT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rocket Pharmaceuticals Sells $180M Rare Disease Review Voucher, Extends Cash Runway to 2028: Rocket Pharmaceuticals has agreed to sell its Rare Pediatric Disease Priority Review Voucher for $180 million following FDA accelerated approval of KRESLADI. The transaction boosts non-dilutive capital and extends the company's cash runway into Q2 2028 to advance cardiovascular gene therapy programs targeting Danon disease, PKP2-ACM and BAG3-DCM.
| Metric | Value |
|---|---|
| Price | $3.03 |
| Market Cap | $335.22M |
| P/E Ratio | -1.47 |
| EPS | $-2.01 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.89 |
| 52-Week Low | $2.19 |
| Volume | 3.32K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-223.12M |
| Gross Margin | 0.00% |
13 analysts cover RCKT: 0 strong buy, 7 buy, 4 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.67.